Carboplatin
As of the edition of 20 October 2026, Carboplatin is a small molecule: marketed, first approved in 1986 (CH).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2003
- Kind
- Small molecule
- Brand name
- Paraplatin
- First approved
- 26 August 1986 (CH)
- Approvals on record
- 16 in 6 regions
- Holder of the most recent approval
- Avyxa; 8 holders in all
- Registered trials
- 2,799, 420 stopped early
- Disease areas
- Cancer; Lungs and airways; Urinary and reproductive; Pregnancy and women's health; Hormones; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 88 | 33 | 24 | 8 |
| Phase 1 | 460 | 254 | 93 | 88 |
| Phase 2 | 1,676 | 709 | 481 | 260 |
| Phase 3 | 544 | 224 | 174 | 61 |
| Phase 4 | 31 | 7 | 10 | 3 |
| All trials | 2,799 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Earlier holder | 1989 to now |
| Pfizer | Applicant and Lead sponsor of trials | 1997 to now |
| Corden Pharma Latina | Acquired holder | 2012 to now |
| Cordenpharma | Acquired holder | 2013 to now |
| Avyxa | Later holder | 2025 to now |
| Clinigen | Applicant |